Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey T Gibney

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE TrialSamer A Srour, Jad Chahoud, Alexandra Drakaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2014
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanomaGeoffrey T Gibney, Ragini R Kudchadkar, Ronald C DeConti, et al.
Cancers|March 25, 2022
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene FusionsSourat Darabi, Andrew Elliott, David R Braxton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing SchedulesGeorgina V Long, Caroline Robert, Marcus O Butler, et al.
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
Cancer Discovery|December 28, 2014
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotypeKim H T Paraiso, Meghna Das Thakur, Bin Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2018
Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> <sup>V600E</sup>-Mutant MelanomaZeynep Eroglu, Y Ann Chen, Geoffrey T Gibney, et al.
NPJ Precision Oncology|November 14, 2023
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastasesGino K In, Jennifer R Ribeiro, Jun Yin, et al.
American Journal of Hematology|February 13, 2008
Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong KongGeoffrey T Gibney, Carolien I M Panhuysen, Jason C C So, et al.
Journal of Participatory Medicine|May 22, 2026
Developing a Culturally Tailored Narrative Video for Skin Cancer Prevention Among Spanish-Speaking Hispanic Outdoor Workers: Co-Design StudyDavid Perez, Valeria Gómez, Dariana Sedeño-Delgado, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE TrialSamer A Srour, Jad Chahoud, Alexandra Drakaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2014
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanomaGeoffrey T Gibney, Ragini R Kudchadkar, Ronald C DeConti, et al.
Cancers|March 25, 2022
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene FusionsSourat Darabi, Andrew Elliott, David R Braxton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing SchedulesGeorgina V Long, Caroline Robert, Marcus O Butler, et al.
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
Cancer Discovery|December 28, 2014
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotypeKim H T Paraiso, Meghna Das Thakur, Bin Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2018
Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> <sup>V600E</sup>-Mutant MelanomaZeynep Eroglu, Y Ann Chen, Geoffrey T Gibney, et al.
NPJ Precision Oncology|November 14, 2023
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastasesGino K In, Jennifer R Ribeiro, Jun Yin, et al.
American Journal of Hematology|February 13, 2008
Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong KongGeoffrey T Gibney, Carolien I M Panhuysen, Jason C C So, et al.
Journal of Participatory Medicine|May 22, 2026
Developing a Culturally Tailored Narrative Video for Skin Cancer Prevention Among Spanish-Speaking Hispanic Outdoor Workers: Co-Design StudyDavid Perez, Valeria Gómez, Dariana Sedeño-Delgado, et al.
Pageof 6